Qualigen TherapeuticsQLGN
About: Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
Employees: 4
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0.87% less ownership
Funds ownership: 2.33% [Q3] → 1.46% (-0.87%) [Q4]
42% less funds holding
Funds holding: 19 [Q3] → 11 (-8) [Q4]
57% less capital invested
Capital invested by funds: $107K [Q3] → $45.5K (-$61.3K) [Q4]
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 7
Research analyst outlook
We haven’t received any recent analyst ratings for QLGN.
Financial journalist opinion









